Ekso Bionics Reports Certain Preliminary Fourth Quarter 2024 Financial Results
Ekso Bionics (NASDAQ: EKSO) has announced preliminary Q4 2024 financial results, expecting record revenues between $5.0-$5.1 million, up from $4.8 million in Q4 2023. The company highlighted progress with initial CMS reimbursement for Ekso Indego Personal, expanding Medicare patient access.
Cash position as of December 31, 2024, stood at $6.5 million, down from $8.6 million year-over-year. Net cash used in operations for Q4 2024 was approximately $1.5 million, slightly improved from $1.6 million in Q4 2023. The company notes these are preliminary unaudited results subject to potential adjustments during the final review process.
Ekso Bionics (NASDAQ: EKSO) ha annunciato i risultati finanziari preliminari per il quarto trimestre del 2024, prevedendo ricavi record compresi tra 5,0 e 5,1 milioni di dollari, in aumento rispetto ai 4,8 milioni di dollari del quarto trimestre del 2023. L'azienda ha evidenziato i progressi nella riqualificazione iniziale dei pagamenti CMS per l'Ekso Indego Personal, ampliando l'accesso dei pazienti a Medicare.
Alla data del 31 dicembre 2024, la posizione di cassa si attestava a 6,5 milioni di dollari, in calo rispetto agli 8,6 milioni dell'anno precedente. Il flusso di cassa netto utilizzato per le operazioni nel quarto trimestre del 2024 è stato di circa 1,5 milioni di dollari, leggermente migliorato rispetto a 1,6 milioni di dollari nel quarto trimestre del 2023. L'azienda fa notare che questi sono risultati preliminari non verificati soggetti a potenziali aggiustamenti durante il processo di revisione finale.
Ekso Bionics (NASDAQ: EKSO) ha anunciado los resultados financieros preliminares del cuarto trimestre de 2024, esperando ingresos récord entre 5.0 y 5.1 millones de dólares, un aumento desde los 4.8 millones de dólares en el cuarto trimestre de 2023. La empresa destacó avances en la reembolsación inicial de CMS para el Ekso Indego Personal, ampliando el acceso de los pacientes a Medicare.
La posición de efectivo al 31 de diciembre de 2024 era de 6.5 millones de dólares, una disminución desde los 8.6 millones del año anterior. El efectivo neto utilizado en operaciones para el cuarto trimestre de 2024 fue de aproximadamente 1.5 millones de dólares, ligeramente mejor que los 1.6 millones de dólares del cuarto trimestre de 2023. La empresa señala que estos son resultados preliminares no auditados sujetos a posibles ajustes durante el proceso de revisión final.
엑스코 바이오닉스 (NASDAQ: EKSO)는 2024년 4분기 재무 실적을 잠정적으로 발표하며, 500만~510만 달러의 기록적인 수익을 예상하고 있습니다. 이는 2023년 4분기의 480만 달러에서 증가한 수치입니다. 회사는 메디케어 환자의 접근성을 확대하는 Ekso Indego Personal에 대한 초기 CMS 재정 지원의 진전을 강조했습니다.
2024년 12월 31일 기준 현금 보유액은 650만 달러로, 전년동기 대비 860만 달러에서 감소했습니다. 2024년 4분기 운영에 사용된 순현금은 약 150만 달러로, 2023년 4분기의 160만 달러에서 약간 개선되었습니다. 회사는 이는 최종 검토 과정에서 조정될 수 있는 잠정적인 비감사 결과라고 언급했습니다.
Ekso Bionics (NASDAQ: EKSO) a annoncé des résultats financiers préliminaires pour le quatrième trimestre 2024, s'attendant à des revenus records compris entre 5,0 et 5,1 millions de dollars, en hausse par rapport à 4,8 millions de dollars au quatrième trimestre 2023. L'entreprise a souligné les progrès concernant le remboursement initial par le CMS pour l'Ekso Indego Personal, élargissant l'accès des patients à Medicare.
La position de trésorerie au 31 décembre 2024 était de 6,5 millions de dollars, en baisse par rapport à 8,6 millions de dollars un an auparavant. La trésorerie nette utilisée dans les opérations pour le quatrième trimestre 2024 était d'environ 1,5 million de dollars, légèrement meilleure que les 1,6 million de dollars du quatrième trimestre 2023. L'entreprise précise qu'il s'agit de résultats préliminaires non audités, soumis à d'éventuels ajustements lors du processus de révision final.
Ekso Bionics (NASDAQ: EKSO) hat vorläufige Finanzzahlen für das vierte Quartal 2024 bekannt gegeben und erwartet Rekordumsätze zwischen 5,0 und 5,1 Millionen Dollar, ein Anstieg von 4,8 Millionen Dollar im vierten Quartal 2023. Das Unternehmen hob Fortschritte bei der ersten CMS-Erstattung für das Ekso Indego Personal hervor und erweitert dadurch den Zugang für Medicare-Patienten.
Die Liquiditätsposition zum 31. Dezember 2024 betrug 6,5 Millionen Dollar, ein Rückgang von 8,6 Millionen Dollar im Jahresvergleich. Der Nettobetrag an Bargeld, der für den Betrieb im vierten Quartal 2024 verwendet wurde, betrug etwa 1,5 Millionen Dollar, was eine leichte Verbesserung gegenüber 1,6 Millionen Dollar im vierten Quartal 2023 darstellt. Das Unternehmen weist darauf hin, dass dies vorläufige, nicht geprüfte Ergebnisse sind, die während des endgültigen Prüfungsprozesses möglicherweise angepasst werden könnten.
- Expected record quarterly revenue of $5.0-$5.1M, up from $4.8M YoY
- Secured CMS reimbursement approval for Ekso Indego Personal
- Reduced cash burn to $1.5M from $1.6M YoY
- Cash position declined to $6.5M from $8.6M YoY
- Continuing operational cash burn of $1.5M per quarter
Insights
The preliminary Q4 2024 results reveal both promising and concerning aspects for EKSO. The projected revenue of
The cash position warrants attention - declining from
The CMS reimbursement approval for Ekso Indego Personal is a important catalyst that could accelerate revenue growth, but the pipeline build-out will take time to materially impact financials. For a
The CMS reimbursement milestone for Ekso Indego Personal represents a pivotal development in the medical exoskeleton market. Medicare coverage significantly expands the addressable market by providing access to the 65+ age demographic - a key target population for mobility assistance devices. The reimbursement pathway typically drives adoption among private insurers, potentially creating a multiplier effect for market penetration.
However, the modest sequential revenue growth suggests the reimbursement impact hasn't yet translated to substantial sales acceleration. Building a Medicare claims pipeline requires significant investment in reimbursement support infrastructure and healthcare provider education. The sales cycle for medical devices with new reimbursement coverage typically spans 12-18 months as providers adapt their procurement and billing processes.
Expects Record Revenues for the Fourth Quarter of 2024
SAN RAFAEL, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the quarter ended December 31, 2024.
Total revenue for the fourth quarter of 2024 is estimated to be in the range of
“We made significant progress in 2024, highlighted by initial CMS reimbursement for our Ekso Indego Personal,” said Scott Davis, the Company’s Chief Executive Officer. “With expanded access of this transformative device to Medicare-covered patients, we remain focused on building upon our growing CMS claim pipeline. At the same time, we continue to bolster demand for our flagship EksoNR device as we execute on our long-term growth strategy.”
Estimated cash as of December 31, 2024 was
The estimated, projected or anticipated financial results, financial condition or other financial information discussed in this press release are based on management’s preliminary unaudited analysis of financial results for the quarter ended December 31, 2024. As of the date of this press release, the Company has not completed its financial statement reporting process for the quarter ended December 31, 2024, and the Company’s independent registered accounting firm has not audited the preliminary financial data discussed in this press release. During the course of the Company’s quarter-end closing procedures and review process, including the finalization of its financial statements for and as of the quarter ended December 31, 2024, the Company may identify items that would require it to make adjustments, which may be material to the information presented above. As a result, the estimates above constitute forward-looking information and are subject to risks and uncertainties, including possible adjustments to preliminary results. The Company expects to report complete fourth quarter and full year 2024 financial results during the first week of March 2025.
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: www.eksobionics.com or follow @EksoBionics on X.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the estimated financial results, the Company’s growing CMS claim pipeline and the Company’s ability to bolster demand for its EksoNR devices and execute on its long-term strategy. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, changes resulting from the Company’s finalization of its financial statements for and as of the quarter ended December 31, 2024, information or new changes in facts or circumstances that may occur prior to the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 that are required to be included in such annual report, the Company's inability to obtain adequate financing to fund and grow the Company's operations and necessary to develop or enhance the Company’s technology, the Company’s inability to successfully collaborate with its network of existing neuro-rehabilitation facilities, physicians, and DMEs in seeking CMS reimbursements, the Company’s inability to obtain future reimbursements from CMS in a timely manner and at the expected reimbursement levels, the Company’s inability to obtain insurance coverage beyond CMS, the Company’s inability to obtain additional indications of use for its devices, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of the Company’s sales and marketing efforts or of partners to market the Company’s products effectively, adverse results in future clinical studies of the Company's medical device products, the failure of the Company to obtain or maintain patent protection for the Company's technology, the failure of the Company to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, disruptions in the Company’s supply chain, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company’s most recently filed Annual Report on Form 10-K and its subsequently filed Quarterly Reports on Form 10-Q. To learn more about the Company please visit the Company’s website at www.eksobionics.com or refer to the Company’s X page at @EksoBionics. Any forward-looking statements made in this press release speak only as of the date of this press release. The Company does not undertake to update these forward-looking statements, except as required by law.
Contacts:
Investors:
David Carey
FINN Partners
212-867-1768
investors@eksobionics.com
FAQ
What is Ekso Bionics' (EKSO) expected revenue for Q4 2024?
How much cash does EKSO have as of December 31, 2024?
What was EKSO's cash burn rate in Q4 2024?
What major milestone did EKSO achieve with CMS in 2024?
